Table 5.
IPA results for Toxicological analysis.
| Organ system | Name | P-value range | Number of molecules involved |
|---|---|---|---|
| A. Top toxicological functions with HCA–Normoxia compared with No HCA–Normoxia (control) | |||
| Cardiotoxicity | Cardiac enlargement | 1–1.99E−05 | 76 |
| Cardiac infarction | 1– 2.67E−05 | 53 | |
| Cardiac dysfunction | 5.86E−01–4.49E−05 | 59 | |
| Cardiac arteriopathy | 4.67E−01–1.26E−04 | 72 | |
| Cardiac necrosis/cell death | 4.67E−01–1.15E−03 | 30 | |
| Hepatotoxicity | Liver hyperplasia/hyperproliferation | 1–2.47E−27 | 575 |
| Liver necrosis/cell death | 3.05E−01–6.35E−11 | 48 | |
| Hepatocellular carcinoma | 1– 1.02E−09 | 231 | |
| Liver steatosis | 2.59E−01–2.88E−09 | 78 | |
| Liver damage | 1–4.16E−09 | 47 | |
| Nephrotoxicity | Renal necrosis/cell death | 1–7.48E−10 | 68 |
| Renal damage | 2.28E−01–1.18E−05 | 42 | |
| Renal inflammation | 5.68E−01–9.00E−05 | 49 | |
| Renal nephritis | 5.68E−01–9.00E−05 | 48 | |
| Nephrosis | 1.24E−01–1.71E−04 | 21 | |
| B. Top toxicological functions with no HCA–Hyperoxia compared with No HCA–Normoxia (control) | |||
| Cardiotoxicity | Cardiac arteriopathy | 3.20E−01–4.12E−04 | 33 |
| Cardiac infarction | 3.68E−01–1.05E−03 | 25 | |
| Cardiac inflammation | 3.68E−01–3.27E−03 | 9 | |
| Pulmonary hypertension | 1–4.73E−03 | 5 | |
| Cardiac enlargement | 1– 3.61E−02 | 23 | |
| Hepatotoxicity | Liver hyperplasia/hyperproliferation | 5.55E−01–8.46E−14 | 254 |
| Hepatocellular carcinoma | 5.55E−01–1.24E−06 | 107 | |
| Liver damage | 5.12E−01–4.40E−05 | 17 | |
| Liver fibrosis | 3.39E−01–5.42E−03 | 23 | |
| Liver steatosis | 1.14E−01–6.25E−03 | 28 | |
| Nephrotoxicity | Renal damage | 5.12E−01–1.07E−04 | 22 |
| Renal proliferation | 1.51E−01–6.61E−03 | 13 | |
| Renal necrosis/cell death | 5.16E−01–8.89E−03 | 22 | |
| Renal inflammation | 4.79E−01–1.31E−02 | 22 | |
| Renal nephritis | 4.79E−01–1.31E−02 | 22 | |
| C. Top toxicological functions with HCA–hyperoxia compared with No HCA–Normoxia (control) | |||
| Cardiotoxicity | Cardiac infarction | 1– 2.62E−11 | 84 |
| Cardiac enlargement | 1– 2.08E−09 | 108 | |
| Pulmonary hypertension | 3.66E−01–8.17E−08 | 42 | |
| Cardiac dysfunction | 1– 1.39E−05 | 77 | |
| Cardiac necrosis/cell death | 4.95E−01–1.40E−05 | 45 | |
| Hepatotoxicity | Liver hyperplasia/hyperproliferation | 1–1.23E−31 | 753 |
| Hepatocellular carcinoma | 1–3.31E−16 | 323 | |
| Liver steatosis | 4.34E−01–2.36E−13 | 108 | |
| Liver necrosis/cell death | 4.87E−01–7.82E−11 | 57 | |
| Liver inflammation/hepatitis | 1–1.15E−10 | 87 | |
| Nephrotoxicity | Renal necrosis/cell death | 5.23E−01–9.78E−13 | 94 |
| Kidney failure | 4.34E−01–1.81E−07 | 46 | |
| Renal inflammation | 5.23E−01–3.24E−07 | 75 | |
| Renal nephritis | 5.23E−01–3.24E−07 | 74 | |
| Glomerular injury | 1–4.28E−07 | 97 | |